Abstract: Provide is a method for preventing or treating a kidney disease. The method employs an adenine-induced mouse renal failure model to evaluate the therapeutic effects of LY2922470 and TAK875 on renal failure. The results demonstrate that LY2922470 has a therapeutic effect on renal failure, and this effect is not directly related to the GPR40 target. Additionally, an in vitro renal fibrosis model confirms that LY2922470 inhibits renal fibrosis. The significant potential of LY2922470 as a therapeutic agent for kidney diseases is verified. For the first time, it is revealed that LY2922470 effectively improves renal function, providing a promising novel candidate drug for the treatment of renal injury, chronic kidney disease, and renal failure. This expands the indications of LY2922470 and substantially enhances its application potential and market prospects.

Abstract: A method for preventing or treating a cerebrovascular disease or a tissue ischemia-reperfusion injury is provided. The method comprises administering to a patient a drug containing a pharmaceutically effective amount of LY2922470. The embodiments of the present disclosure confirm the significant potential of LY2922470 as a drug for cerebrovascular diseases and tissue ischemia-reperfusion injury. For the first time, it is disclosed that LY2922470 effectively improves infarct lesions, providing an effective new potential alternative drug for the treatment of related cerebrovascular diseases and tissue ischemia-reperfusion injury, expanding the indications of LY2922470, and greatly enhancing the application potential and market prospects of LY2922470.